<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489099</url>
  </required_header>
  <id_info>
    <org_study_id>V232-054</org_study_id>
    <secondary_id>2007_565</secondary_id>
    <nct_id>NCT00489099</nct_id>
  </id_info>
  <brief_title>A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)</brief_title>
  <official_title>A Study in Healthy Young Adults To Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability, and immunogenicity of a recombinant hepatitis B
      vaccine manufactured using an upgrade to the production process. The primary hypotheses
      tested at 1 month after the third dose of vaccine are the following: 1) the 3 lots of the
      process upgrade vaccine induce similar seroprotection rates to hepatitis B surface antigen
      (HBsAg), 2) the combined lots of the process upgrade vaccine induce adequate seroprotection
      to HBsAg, and 3) the process upgrade vaccine will induce geometric mean antibody titers to
      HBsAg that are non-inferior or superior to those induced by the current process vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Seroprotection to Hepatitis B Surface Antigen</measure>
    <time_frame>1 month after the third vaccination (Month 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers to Hepatitis B Surface Antigen</measure>
    <time_frame>1 month after the third vaccination (Month 7)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Adverse Experience</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Injection-site Adverse Experience</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Systemic Adverse Experience</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Fever (&gt;=37.8°C, 100.0°F)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">860</enrollment>
  <condition>Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V232 Current Process Hepatitis B Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V232 Modified Process Hepatitis B Vaccine: Lot A</intervention_name>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V232 Modified Process Hepatitis B Vaccine: Lot B</intervention_name>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V232 Modified Process Hepatitis B Vaccine: Lot C</intervention_name>
    <arm_group_label>V232 Modified Process Hepatitis B Vaccine: Lot C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V232 Current Process Hepatitis B Vaccine</intervention_name>
    <arm_group_label>V232 Current Process Hepatitis B Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In general good health

          -  Female participants have a negative pregnancy test just prior to vaccination on Day 1

        Exclusion Criteria:

          -  History of Hepatitis B Infection or vaccination

          -  Known or suspected hypersensitivity to any component of Recombivax HB™ vaccine (e.g.,
             aluminum, yeast)

          -  Administration of hepatitis B immune globulin, serum immune globulin, or any other
             blood-derived product within 3 months prior to vaccination on Day 1

          -  Receipt of an inactivated virus vaccine within 14 days or a live virus vaccine within
             30 days prior to vaccination on Day 1

          -  Participation on prior study using an investigational drug or vaccine in prior 3
             months

          -  Known or suspected impairment of immunologic function or recent use of
             immunomodulatory medications, excluding topical or inhaled steroids

          -  Pregnant or nursing women or women planning to become pregnant within the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin. 2009 Feb;5(2):92-7. Epub 2009 Feb 14. Erratum in: Hum Vaccin Immunother. 2017 Apr 3;13(4):965.</citation>
    <PMID>18690015</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

